Table 2.

ASCs or CM treatment attenuates the cardiac dysfunction in PF (Early phase)

	Con (n = 8)	B (n = 8)	B + M (n = 6)	BAD3 (n = 7)	BCM3 (n = 8)
RVSP	28.64 ± 1.04	45.55 ± 2.49a	46.98 ± 2.82a	33.29 ± 1.59b	34.84 ± 3.94b , c
RV/LV + S	0.27 ± 0.01	0.40 ± 0.02a	0.39 ± 0.02a	0.33 ± 0.02b	0.32 ± 0.01b , c
RV/LV EDA	0.31 ± 0.02	0.64 ± 0.05a	0.68 ± 0.05a	0.38 ± 0.02b	0.36 ± 0.02b , c
RV/LV EF	0.71 ± 0.01	0.53 ± 0.04a	0.54 ± 0.03a	0.65 ± 0.03b	0.64 ± 0.02b , c

ASCs or CM were injected through the jugular vein after 3 days of Bleo instillation. Following 2 weeks of Bleo instillation, ECHO and haemodynamic parameters were assessed. Data demonstrate the improvement of cardiac function and haemodynamics in the Bleo animals in presence of ASCs or CM. Data presented are mean ± SEM, Con (n = 8), B (n = 8), B + M (n = 6), BAD3 (n = 7), and BCM3 (n = 8).

^a P ≤ 0.05, comparing B and B + M animals against the controls.

^b P ≤ 0.05, comparing BAD3 and BCM3 versus B.

^c P ≤ 0.05, comparing BCM3 versus B + M.